New chemo delivery method targets pancreatic cancer before surgery

NCT ID NCT05634720

Ongoing Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests giving a single dose of chemotherapy directly into the liver artery before standard surgery and systemic chemo for localized pancreatic cancer. The goal is to see if this approach is safe and feasible in 20 patients. Researchers hope it may help prevent the cancer from spreading to the liver.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hepatic artery chemotherapy (FUDR/oxaliplatin)
What this could lead to: If successful, this could point toward a new way to deliver chemotherapy directly to the liver before surgery, potentially reducing cancer spread in pancreatic cancer patients.
What could go wrong: This is a very small, early-stage safety study with only 20 participants. It is not designed to prove the treatment works, and there may be side effects from the chemotherapy or the procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Duke University Health System

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.